Septerna Inc
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SEPN research report →
Range $43 – $60
Price Chart
About the company
Septerna, Inc. , a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM for graves’ disease and thyroid eye disease.
- CEO
- Jeffrey T. Finer
- IPO
- 2024
- Employees
- 130
- HQ
- South San Francisco, CA, US
Get TickerSpark's AI analysis on SEPN
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.84B
- P/E
- -75.54
- PEG
- -0.42
- P/S
- 18.59
- P/B
- 4.75
- EV/EBITDA
- -44.69
- Div Yield
- 0.00%
- Gross Margin
- 99.57%
- Op Margin
- -44.04%
- Net Margin
- -24.51%
- ROE
- -6.31%
- ROIC
- -8.89%
Latest fiscal year · YoY change
- Revenue
- $45.95M+4174.5%
- Gross Profit
- $45.95M+4174.5%
- Op Income
- $-80,797,000
- Net Income
- $-48,879,000+31.9%
- EPS
- $-1.10+43.0%
- OCF Growth
- +263.3%
- FCF Growth
- +257.6%
- 52W High
- $51.10
- 52W Low
- $10.91
- 50D MA
- $36.46
- 200D MA
- $28.54
- Beta
- 2.28
- RSI (14)
- 54
- Avg Volume
- 440.36K
No earnings-call transcripts are available for SEPN yet.
- Free Float
- 41.9%
- Shares Outstanding
- 45.08M
- Float Shares
- 18.88M
of shares held by institutions
125 13F filers
Buy/sell ratio 0.57. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Ra Capital Management, L.P. | 7.00M | 0 |
| Trv Gp V, LLC | 6.22M | 0 |
| Driehaus Capital Management LLC | 4.43M | ▲ 37.49K |
| Trv Gp Vi, LLC | 4.21M | 0 |
| Samsara Biocapital, LLC | 3.15M | 0 |
| Goldman Sachs Group Inc | 3.06M | ▲ 156.34K |
| Blackrock, Inc. | 1.93M | ▲ 109.91K |
| Siren, L.L.C. | 1.90M | ▼ 100.00K |
| Vanguard Group Inc | 1.51M | ▼ 10.56K |
| Avoro Capital Advisors LLC | 1.34M | 0 |
| Vanguard Capital Management LLC | 1.22M | ▲ 24.71K |
| Primecap Management Co | 1.17M | ▲ 118.55K |
Held by 182 ETFs
Biggest fund positions in SEPN by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 12, 26 | Third Rock Ventures V, L.P. | sell | 147,059 |
| Aug 12, 26 | Third Rock Ventures V, L.P. | sell | 141 |
| Aug 12, 26 | RA CAPITAL MANAGEMENT, L.P. | sell | 746,500 |
| Aug 12, 26 | RA CAPITAL MANAGEMENT, L.P. | sell | 746,500 |
| Aug 11, 26 | Bhatt Elizabeth | other | 6,319 |
| Aug 11, 26 | Bhatt Elizabeth | other | 18,681 |
| Aug 11, 26 | Bhatt Elizabeth | sell | 25,000 |
| Aug 11, 26 | Bhatt Elizabeth | other | 6,319 |
| Aug 11, 26 | Bhatt Elizabeth | other | 18,681 |
| Aug 3, 26 | Long Daniel D. | other | 1,518 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our SEPN coverage
Recent articles, reports, and earnings notes.
No research on SEPN yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate SEPN report →Septerna, Inc. (SEPN) Reports Q2 Loss, Beats Revenue Estimates
zacks.com · Aug 10
Septerna's Chief People Officer Sold Nearly 12,000 Company Shares. What Does That Mean for Investors?
fool.com · Jul 5
Is Septerna a Stock to Sell After an Insider Let Go of 15,000 Shares?
fool.com · Jun 29
Septerna to Present Preclinical Characterization of SEP-479, an Oral PTH1R Agonist for Hypoparathyroidism, at 2026 ENDO Annual Meeting
businesswire.com · Jun 8
Septerna, Inc. (SEPN) Presents at Bank of America Global Healthcare Conference 2026 Transcript
seekingalpha.com · May 13
Septerna, Inc. (SEPN) Reports Q1 Loss, Tops Revenue Estimates
zacks.com · May 11
Septerna Highlights Business Progress and Reports First Quarter 2026 Financial Results
globenewswire.com · May 11
Septerna to Present at Bank of America Securities Health Care Conference
globenewswire.com · May 5
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.